Does Vitamin K2 Lower Cholesterol?

Vitamin K2 supplements do not appear to lower cholesterol in humans based on the clinical trial evidence available. A systematic review and meta-analysis pooling data from nine trials found no meaningful change in total cholesterol, LDL, HDL, or triglycerides following vitamin K supplementation. That result surprises many people, because animal studies tell a more encouraging story and because K2 does seem to benefit cardiovascular health through a completely different route. The disconnect between what happens in a lab mouse and what happens in your bloodwork is real, and worth understanding.

What Human Trials Actually Show

The most comprehensive look at this question comes from a 2023 meta-analysis published in the Journal of Nutritional Science. Pooling results from multiple randomized controlled trials, it found that vitamin K supplementation produced no significant effect on total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, or C-reactive protein (a marker of inflammation).¹ The changes were essentially zero across the board, not even trending in a favorable direction.

Individual trials reinforce this. A randomized controlled trial giving people with type 2 diabetes 360 micrograms of MK-7 (a common form of K2) daily for 12 weeks found improvements in blood sugar control but no significant variation in lipid profiles.² A cross-sectional study looking at dietary vitamin K intake and blood lipids in people with cardiovascular disease found that HDL cholesterol was not influenced by total daily vitamin K intake.³

A post-hoc analysis of the AVADEC trial, which gave older men high-dose vitamin K2 and vitamin D3 for two years, found no corresponding changes in inflammatory markers either. Even though the supplements successfully lowered a biomarker of vitamin K deficiency and raised vitamin D levels, the downstream effects on inflammation and fat tissue around the heart were absent.⁴ So even in a long trial with adequate doses, the lipid needle did not move.

Why Animal Studies Look More Promising

If you have encountered claims that vitamin K2 lowers cholesterol, they likely trace back to animal research. In rabbits fed a high-cholesterol diet, vitamin K2 treatment clearly lowered total cholesterol in the blood, reduced cholesterol deposits in the aorta, and slowed the progression of atherosclerotic plaques.⁵ In another rabbit study, co-supplementation of vitamin K2 and selenium lowered cholesterol, triglycerides, and LDL while raising HDL compared to placebo.⁶

Mouse research has even identified a molecular pathway that could explain the effect. In mice on a high-fat diet, vitamin K supplementation reduced blood lipid levels and activated a signaling cascade in the liver involving a protein called Gas6, which regulates how the liver processes fat.⁷ That mechanism is real and well-documented in rodents. The problem is that it has not translated into measurable lipid changes in human trials.

This gap between animal studies and human outcomes is not unusual in nutrition research. Rodents and rabbits metabolize fats differently, respond to much higher relative doses, and are often fed extreme diets designed to produce disease quickly. A rabbit eating a diet engineered to jack up its cholesterol is not the same as a person with mildly elevated LDL. When the human data says “no effect” and the animal data says “strong effect,” the human data wins for practical purposes.

How K2 Benefits the Heart Without Touching Cholesterol

The reason vitamin K2 keeps appearing in cardiovascular research has little to do with cholesterol. Its primary heart-related function involves calcium. Vitamin K2 activates a protein called matrix Gla protein, or MGP, which is one of the body’s main defenses against calcium buildup in artery walls.⁸ Without enough vitamin K, MGP stays inactive, and calcium can accumulate in soft tissues where it does not belong, particularly blood vessels.⁹

Arterial calcification is a risk factor for heart disease that is largely independent of cholesterol. You can have pristine LDL levels and still develop calcified arteries, or you can have elevated cholesterol but relatively clean vessels. K2’s value appears to lie in keeping arteries flexible and free of mineral deposits, not in reducing the amount of fat circulating in your blood. This distinction matters because people often assume any supplement labeled “heart healthy” must be working through cholesterol, and K2 is not doing that.

What the Large Observational Studies Found

Two major population studies have linked higher vitamin K2 intake to better cardiovascular outcomes. The Rotterdam Study, which followed thousands of older Dutch adults, found that people in the highest third of dietary menaquinone (K2) intake had a substantially lower risk of dying from coronary heart disease compared to those in the lowest third. The association also held for all-cause mortality and severe aortic calcification. Vitamin K1 intake, by contrast, showed no relationship with any of these outcomes.¹⁰

The Danish Diet Cancer and Health Study, a large prospective cohort, found that people with the highest K2 intakes had about a 14% lower risk of being hospitalized for atherosclerotic cardiovascular disease compared to those with the lowest intakes.¹¹ This study also found similar inverse associations with K1, suggesting the benefit may relate to vitamin K’s broader biological roles rather than something unique to K2.

These are observational studies, so they cannot prove cause and effect. People who eat more K2-rich foods (fermented dairy, certain cheeses, natto) may also have other dietary or lifestyle habits that protect their hearts. But the pattern is consistent: higher K2 intake tracks with less cardiovascular disease. The mechanism is more likely the calcification-blocking pathway described above than any cholesterol-lowering action, since the clinical trials show no lipid changes.

The Statin Connection

An unexpected wrinkle in the vitamin K story involves statins. Cholesterol and vitamin K share a common precursor in the body’s biochemical machinery, a compound called geranylgeranyl pyrophosphate (GGPP). Statins, which block cholesterol production in the liver, can also interfere with vitamin K conversion, which could impair the function of vitamin K-dependent proteins like MGP.¹²

This has raised a question in the research community: could long-term statin use inadvertently promote arterial calcification by starving MGP of the vitamin K it needs? The theory is plausible and has some indirect support, but it remains mostly theoretical. No large trial has tested whether adding K2 to a statin regimen reduces calcification more than statin therapy alone. If you are taking a statin and considering K2 supplementation, the evidence does not suggest harm (outside of anticoagulant interactions, discussed below), but it also does not confirm a benefit specific to statin users.

MK-4 Versus MK-7 and Why the Form Matters

Vitamin K2 is not a single molecule. It comes in several subtypes, the most discussed being MK-4 (menaquinone-4) and MK-7 (menaquinone-7). MK-4 is found in animal-derived foods like egg yolks and butter. MK-7 comes from bacterial fermentation, most famously the Japanese food natto, and is the form used in most K2 supplements sold today.

The two forms behave differently in the body. A head-to-head bioavailability study in healthy women found that a single dose of MK-7 raised blood levels of the vitamin, peaking at about six hours and remaining detectable 48 hours later. MK-4, given at the same dose, did not produce detectable blood levels at any time point.¹³ This does not mean MK-4 is useless; it may be taken up rapidly by tissues and converted locally. But for sustained blood levels, MK-7 is clearly superior, which is why most modern supplement research and most over-the-counter products use it.

Neither form has demonstrated cholesterol-lowering effects in human trials. The bioavailability difference matters more for K2’s other functions (bone health, calcification inhibition) than for any lipid effect, because there does not appear to be a lipid effect to optimize.

Individual Variation and Triglycerides

One intriguing finding suggests that your existing lipid levels may influence how your body responds to vitamin K supplementation, even if the supplement does not change those lipid levels in return. Research has found that people with higher triglycerides at the start of supplementation tend to show a stronger rise in blood levels of phylloquinone (vitamin K1) after taking supplements, with the relationship being more pronounced in men than in women.¹⁴ Total cholesterol, LDL, and HDL did not predict the response in the same way.

This makes biological sense. Vitamin K is fat-soluble, and fat-soluble vitamins hitch a ride on lipoproteins in the bloodstream. People with more triglyceride-rich particles circulating may simply have more transport vehicles available to carry the vitamin. The practical upshot is that two people taking the same K2 supplement could end up with quite different blood levels, and your baseline metabolic profile may partly explain why. But this is about how well you absorb the vitamin, not about whether the vitamin changes your cholesterol.

Insulin Sensitivity and Metabolic Health

Some supplement marketers bundle K2 into “metabolic health” stacks alongside claims about blood sugar, inflammation, and cholesterol. The evidence here is mixed and mostly disappointing. A meta-analysis of vitamin K supplementation studies found no effect on insulin sensitivity, fasting blood glucose, fasting insulin, C-reactive protein, adiponectin, leptin, or interleukin-6.¹⁵ The one trial mentioned earlier that found blood sugar improvements in people with type 2 diabetes is an outlier in the broader literature, and even that trial found no lipid changes.

Mouse research has explored whether K2 could help with fatty liver disease, but one study found that the mechanism did not appear to work through the expected pathway involving osteocalcin, a bone-related protein that K2 helps activate.¹⁶ The science here is genuinely early-stage, and it would be premature to take K2 expecting it to meaningfully change your metabolic bloodwork.

Safety and the Warfarin Warning

Vitamin K2 is generally safe for most people at typical supplement doses. It does not thin or thicken the blood in people who are not on anticoagulants. But if you take warfarin or a similar vitamin K antagonist, K2 supplements can be genuinely dangerous.

Warfarin works by blocking the vitamin K cycle, and any extra vitamin K coming in from supplements can counteract the drug. A dose-response study in healthy volunteers found that as little as 10 micrograms of MK-7 per day caused a clinically relevant drop in anticoagulation in some individuals, and 45 micrograms (a standard supplement dose) significantly decreased the INR, the measure of how effectively warfarin is working.¹⁷ The researchers concluded that MK-7 supplements should be avoided entirely in patients on vitamin K antagonist therapy. A separate study modeled the effect of higher K2 doses around catheter ablation procedures and found similar interference with warfarin activity.¹⁸

Newer anticoagulants like rivaroxaban, apixaban, and dabigatran do not work through the vitamin K cycle, so K2 supplementation is not expected to interfere with them. But if you take any blood thinner, mention K2 supplements to your prescriber before starting them.

Where the Confusion Comes From

The persistent belief that K2 lowers cholesterol likely comes from several converging misunderstandings. First, the animal data is genuinely impressive, and supplement companies are not always careful about distinguishing mouse results from human results. Second, the observational studies linking K2 intake to lower heart disease risk are often reported in popular media without explaining the mechanism, leaving readers to assume cholesterol must be involved. Third, the calcification story is harder to explain than “lowers your LDL,” so marketers default to the simpler cholesterol narrative even though it is not supported.

There is also a subtler problem: some early-stage research into the shared biochemical pathways between vitamin K and cholesterol (the GGPP connection, the Gas6 signaling pathway) generates legitimate scientific interest that then gets translated into premature supplement claims. A plausible molecular mechanism in a cell study or a mouse liver is not the same as a proven effect in a person. Researchers in a 2023 review noted that vitamin K supplementation holds potential for managing hyperlipidemia, framing it as a possible future avenue for research, not a current recommendation. That cautious language rarely survives the journey to a product label.

If you are looking for a supplement to lower cholesterol, the evidence does not support K2 for that purpose. If you are interested in K2 for its effects on arterial calcification, bone health, or as general nutritional insurance, those are better-supported reasons to consider it, provided you are not on warfarin. The heart benefits associated with K2 in observational studies are real and consistent, but they appear to work through calcium metabolism in your arteries, not through the cholesterol numbers on your lab report.